<?xml version='1.0' encoding='utf8' standalone='yes'?>
<collection><document><id>7323037</id><passage><infon key="name_1">surname:Goodarzi;given-names:Azadeh</infon><infon key="article-id_other">DTH-20-1078.R2</infon><infon key="article-id_pmid">32558193</infon><infon key="name_0">surname:Najar Nobar;given-names:Niloufar</infon><infon key="year">2020</infon><infon key="article-id_pmc">7323037</infon><infon key="article-id_publisher-id">DTH13867</infon><infon key="fn">This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dth.13867.</infon><infon key="alt-title">Nobar and Goodarzi</infon><infon key="article-id_doi">10.1111/dth.13867</infon><infon key="type">front</infon><infon key="elocation-id">e13867</infon><infon key="license">This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</infon><infon key="section_type">TITLE</infon><infon key="journal">Dermatol Ther; 2020 Jun 18 13867. doi:10.1111/dth.13867</infon><infon key="kwd">COVID-19 corona virus novel human coronavirus (SARS-CoV-2) cutaneous skin manifestation specific skin disease concurrent concomitant simultaneous systematic review pemphigus pemphigoid immunobullous psoriasis psoriatic arthritis immunosuppressive immunomodulator biologic systemic drug</infon><infon key="authors">Nobari NN, Goodarzi A, </infon><offset>0</offset><text>Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? : A systematic review</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>145</offset><text>Abstract</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>154</offset><text>Background and aim</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>173</offset><text>In patients with dermatologic disorders who are affected by new corona virus, we know little about course (underlying disease and new onset-infection) and the most proper management strategies include both issues that are what this systematic review targets.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>434</offset><text>Method</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>441</offset><text>Databases of PubMed, Scopus, Google Scholar, Medscape and CEBD coronavirus dermatology resource of Nottingham University searched completely and initial 237 articles selected to further review and finally nine articles (including 12 patients) entered to this study.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>707</offset><text>Result</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>714</offset><text>from 12 patients with chronic underlying dermatologic disease treated with systemic therapies, only one patient required ICU admission, the others have been treated for mild- moderate symptoms with conventional therapies. The biologic or immunosuppressive/ Immunomodulator agents has been ceased during the course of disease. The course of COVID-19 its management was as similar as normal populations. Their underlying dermatologic disease was exacerbating from mild to moderate. Their treatment has been continued as before, after the symptoms improved.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1273</offset><text>Conclusion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1284</offset><text>Exacerbation of patients underlying dermatologic disease is mild- moderate. Discontinuing the treatment in the acute period of COVID and the restart after recovery may prevent severe recurrence in these patients.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1499</offset><text>This article is protected by copyright. All rights reserved.</text></passage></document>
</collection>